Hairy cell leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:25:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hairy cell leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy https://clinicaltrials.eu/trial/study-of-obinutuzumab-vemurafenib-and-cobimetinib-for-hairy-cell-leukemia-in-patients-previously-treated-with-purine-analogs-or-unfit-for-chemotherapy/ Wed, 29 Apr 2026 15:04:02 +0000 https://clinicaltrials.eu/trial/study-of-obinutuzumab-vemurafenib-and-cobimetinib-for-hairy-cell-leukemia-in-patients-previously-treated-with-purine-analogs-or-unfit-for-chemotherapy/ This clinical trial is focused on studying a type of blood cancer called Hairy Cell Leukemia (HCL). The study involves patients who have either been previously treated with certain drugs called purine analogs or are not suitable for chemotherapy. The trial will use a combination of three medications: Obinutuzumab, Vemurafenib, and Cobimetinib. These medications are being tested together to see how well they work in treating HCL, especially in patients with a specific genetic change known as the BRAF-V600E mutation.

The purpose of the study is to understand how effective these drugs are in fighting the leukemia. The trial is organized into different groups, where patients will receive the medications in a step-by-step manner. Obinutuzumab is given as an infusion, which means it is administered directly into the bloodstream through a vein. Vemurafenib and Cobimetinib are taken as tablets by mouth. The study will observe how patients respond to these treatments over time.

Participants in the study will be monitored for any side effects and how well the leukemia responds to the treatment. The trial aims to gather information on the safety and effectiveness of the drug combination, including how long patients remain free from the disease and their overall survival. This research is important for developing better treatment options for people with Hairy Cell Leukemia.

]]> Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients https://clinicaltrials.eu/trial/study-of-vemurafenib-and-rituximab-for-untreated-hairy-cell-leukemia-patients/ Wed, 29 Apr 2026 15:02:36 +0000 https://clinicaltrials.eu/trial/study-of-vemurafenib-and-rituximab-for-untreated-hairy-cell-leukemia-patients/ This clinical trial is focused on studying a type of blood cancer called Hairy Cell Leukemia (HCL). The study is exploring a new treatment approach that combines two medications, Vemurafenib and Rituximab, as a chemotherapy-free alternative to the standard treatment with Cladribine. The goal is to determine if this new combination is as effective and less harmful than the traditional treatment. The trial involves patients who have not previously received treatment for their HCL.

Participants in the study will receive either the new combination of Vemurafenib and Rituximab or the standard treatment with Cladribine. The study will monitor the effectiveness of these treatments by looking at how well the cancer responds and how long it takes for the cancer to return, if at all. The study will also assess the side effects experienced by participants to ensure the new treatment is safe.

The trial will take place over several months, with regular check-ups to monitor the health and progress of the participants. The study aims to provide a new treatment option for patients with Hairy Cell Leukemia that is less toxic and potentially more effective than current treatments. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia https://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-hairy-cell-leukemia/ Wed, 29 Apr 2026 14:24:51 +0000 https://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-hairy-cell-leukemia/ This clinical trial is focused on studying a rare type of blood cancer called Hairy Cell Leukemia (HCL), which can be difficult to treat when it comes back or does not respond to previous treatments. The study is testing a new treatment called brexucabtagene autoleucel, also known by its code name KTE-X19. This treatment is a type of cell therapy, which involves using a patient’s own immune cells that are modified to better fight cancer cells. The main goal of the study is to see how effective this treatment is in helping patients with HCL.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into the bloodstream. The study will monitor how patients respond to the treatment over time, looking at how well the cancer responds and how long the response lasts. The study will also track the overall health and survival of the participants, as well as the time it takes before any additional treatment might be needed.

In addition to the main treatment, other medications may be used to support the participants’ health during the study. These include methylprednisolone and dexamethasone, which are corticosteroids that help reduce inflammation, and fludarabine and cyclophosphamide, which are chemotherapy drugs that help prepare the body for the cell therapy. The study aims to provide valuable information on the safety and effectiveness of brexucabtagene autoleucel for people with relapsed or refractory HCL.

]]>